The only mTOR inhibitor approved for cancer treatment is temsirolimus, which was approved in 2007 for renal cell carcinoma patients, and there have been no mTOR inhibitors approved since then. This evidence concerns the gene MTOR and hereditary clear cell renal cell carcinoma.